Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Tardive Dyskinesia (TD) Treatment Drugs Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Status and Forecast (2016-2027)
      • 1.3.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Tardive Dyskinesia (TD) Treatment Drugs Supply by Company

    • 2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Company
    • 2.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Company
    • 2.3 Global Tardive Dyskinesia (TD) Treatment Drugs Price by Company
    • 2.4 Tardive Dyskinesia (TD) Treatment Drugs Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Tardive Dyskinesia (TD) Treatment Drugs Market Status by Category

    • 3.1 Tardive Dyskinesia (TD) Treatment Drugs Category Introduction
      • 3.1.1 Valbenazine
      • 3.1.2 Deutetrabenazine
    • 3.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market by Category
      • 3.2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Category (2016-2021)
      • 3.2.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Category (2016-2021)
      • 3.2.3 Global Tardive Dyskinesia (TD) Treatment Drugs Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Tardive Dyskinesia (TD) Treatment Drugs Market Status by End User/Segment

    • 4.1 Tardive Dyskinesia (TD) Treatment Drugs Segment by End User/Segment
      • 4.1.1 Hospitals
      • 4.1.2 Clinic
      • 4.1.3 Others
    • 4.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market by End User/Segment
      • 4.2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Tardive Dyskinesia (TD) Treatment Drugs Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Tardive Dyskinesia (TD) Treatment Drugs Market Status by Region

    • 5.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market by Region
      • 5.1.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Region
      • 5.1.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Region
    • 5.2 North America Tardive Dyskinesia (TD) Treatment Drugs Market Status
    • 5.3 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Status
    • 5.4 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Status
    • 5.5 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Market Status
    • 5.6 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market Status

    6 North America Tardive Dyskinesia (TD) Treatment Drugs Market Status

    • 6.1 North America Tardive Dyskinesia (TD) Treatment Drugs Market by Country
      • 6.1.1 North America Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Country (2016-2021)
      • 6.1.2 North America Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Status

    • 7.1 Europe Tardive Dyskinesia (TD) Treatment Drugs Market by Country
      • 7.1.1 Europe Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Status

    • 8.1 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market by Country
      • 8.1.1 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Market Status

    • 9.1 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Market by Country
      • 9.1.1 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market Status

    • 10.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market by Country
      • 10.1.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Tardive Dyskinesia (TD) Treatment Drugs Manufacturing Cost Analysis
    • 11.5 Tardive Dyskinesia (TD) Treatment Drugs Sales Channel and Distributors Analysis
      • 11.5.1 Tardive Dyskinesia (TD) Treatment Drugs Sales Channel
      • 11.5.2 Tardive Dyskinesia (TD) Treatment Drugs Distributors
    • 11.6 Tardive Dyskinesia (TD) Treatment Drugs Downstream Major Buyers

    12 Global Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Category and by End User/Segment

    • 12.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Tardive Dyskinesia (TD) Treatment Drugs Forecast by Category
      • 12.2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume Forecast by Category
      • 12.2.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value Forecast by Category
      • 12.2.3 Global Tardive Dyskinesia (TD) Treatment Drugs Price Forecast by Category
    • 12.3 Global Tardive Dyskinesia (TD) Treatment Drugs Forecast by End User/Segment
      • 12.3.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value Forecast by End User/Segment
      • 12.3.3 Global Tardive Dyskinesia (TD) Treatment Drugs Price Forecast by End User/Segment

    13 Global Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Region/Country

    • 13.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Region (2022-2027)
      • 13.1.1 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Tardive Dyskinesia (TD) Treatment Drugs Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Teva Pharmaceutical Industries
      • 14.1.1 Company Information
      • 14.1.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.1.3 Teva Pharmaceutical Industries Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Sanofi
      • 14.2.1 Company Information
      • 14.2.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.2.3 Sanofi Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Pfizer Inc.
      • 14.3.1 Company Information
      • 14.3.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.3.3 Pfizer Inc. Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Novartis AG
      • 14.4.1 Company Information
      • 14.4.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.4.3 Novartis AG Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Neurocrine Biosciences, Inc.
      • 14.5.1 Company Information
      • 14.5.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.5.3 Neurocrine Biosciences, Inc. Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 GlaxoSmithKline plc.
      • 14.6.1 Company Information
      • 14.6.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.6.3 GlaxoSmithKline plc. Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Biogen
      • 14.7.1 Company Information
      • 14.7.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.7.3 Biogen Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Bayer AG
      • 14.8.1 Company Information
      • 14.8.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.8.3 Bayer AG Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 AstraZeneca
      • 14.9.1 Company Information
      • 14.9.2 Tardive Dyskinesia (TD) Treatment Drugs Product Introduction
      • 14.9.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Tardive Dyskinesia (TD) Treatment Drugs market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Tardive Dyskinesia (TD) Treatment Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Valbenazine
      Deutetrabenazine

      Segmented by End User/Segment
      Hospitals
      Clinic
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Teva Pharmaceutical Industries
      Sanofi
      Pfizer Inc.
      Novartis AG
      Neurocrine Biosciences, Inc.
      GlaxoSmithKline plc.
      Biogen
      Bayer AG
      AstraZeneca
      Buy now